EventoEvolution of IL-23 inhibitors for Crohn’s disease management
22 Mar 2022 - 22 Mar 2022
SpeakerSilvio Danese, Italy - Laurent Peyrin-Biroulet, France - Edouard Louis, Belgium - Sebastian Zeissig, Germany - William Sandborn, California
Scarica il Programma
Compila il form di iscrizione
The evolution of biological drugs has made major steps forwards for the treatment of IBD, another mechanism of action is the biologic that inhibit IL-23 and new agents are now coming, new data on new monoclonal antibodies in IL23 are becoming available for the treatment of CD.
The aim of the course is to highlight the recent evolution of IL23 blockers for CD patients.